DK1267909T3 - Fremgangsmåder til blokering af vævsdestruktion ved autoreaktive T-celler - Google Patents

Fremgangsmåder til blokering af vævsdestruktion ved autoreaktive T-celler

Info

Publication number
DK1267909T3
DK1267909T3 DK01933358.2T DK01933358T DK1267909T3 DK 1267909 T3 DK1267909 T3 DK 1267909T3 DK 01933358 T DK01933358 T DK 01933358T DK 1267909 T3 DK1267909 T3 DK 1267909T3
Authority
DK
Denmark
Prior art keywords
cells
methods
autoreactive
polypeptide
purified
Prior art date
Application number
DK01933358.2T
Other languages
Danish (da)
English (en)
Inventor
Yang Liu
Pan Zheng
Xue-Feng Bai
Original Assignee
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found
Application granted granted Critical
Publication of DK1267909T3 publication Critical patent/DK1267909T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
DK01933358.2T 2000-03-29 2001-03-29 Fremgangsmåder til blokering af vævsdestruktion ved autoreaktive T-celler DK1267909T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19281400P 2000-03-29 2000-03-29
PCT/US2001/040390 WO2001072325A1 (en) 2000-03-29 2001-03-29 Methods of blocking tissue destruction by autoreactive t cells

Publications (1)

Publication Number Publication Date
DK1267909T3 true DK1267909T3 (da) 2010-11-08

Family

ID=22711138

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01933358.2T DK1267909T3 (da) 2000-03-29 2001-03-29 Fremgangsmåder til blokering af vævsdestruktion ved autoreaktive T-celler

Country Status (8)

Country Link
EP (1) EP1267909B1 (https=)
JP (1) JP2004500110A (https=)
AT (1) ATE475428T1 (https=)
AU (2) AU2001259792B2 (https=)
CA (1) CA2404340C (https=)
DE (1) DE60142684D1 (https=)
DK (1) DK1267909T3 (https=)
WO (1) WO2001072325A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030106084A1 (en) 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
DK2563385T3 (da) * 2010-04-28 2017-11-06 Oncoimmune Inc Fremgangsmåder til anvendelse af opløselig cd24 til behandling af reumatoid artritis
CN104507537A (zh) * 2012-07-13 2015-04-08 宾夕法尼亚大学董事会 用于调节car t细胞的组合物和方法
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
KR20170037625A (ko) 2014-07-21 2017-04-04 노파르티스 아게 Cll-1 키메라 항원 수용체를 사용한 암의 치료
CN107207597A (zh) * 2014-11-06 2017-09-26 儿研所儿童医学中心 用于癌症和自身免疫疾病的免疫疗法
BR112017022394A2 (pt) * 2015-05-07 2018-07-17 Oncoimmune Inc uso de cd24 para diminuir níveis de colesterol das lipoproteínas de baixa densidade
WO2017025963A1 (en) * 2015-08-10 2017-02-16 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods and pharmaceutical compositions for improving wound healing using cd24
KR20180120145A (ko) * 2016-02-02 2018-11-05 온코이뮨, 아이앤씨. 렙틴-결핍 병태를 치료하기 위한 cd24 단백질의 용도
WO2018165204A1 (en) * 2017-03-07 2018-09-13 Oncoimmune, Inc. Methods of use of soluble cd24 for treating systemic lupus erythematosus
US20200181235A1 (en) * 2017-05-15 2020-06-11 Oncoimmune, Inc. Methods of use of soluble cd24 for neuroprotection and remyelination
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof

Also Published As

Publication number Publication date
WO2001072325A9 (en) 2003-02-20
EP1267909B1 (en) 2010-07-28
CA2404340C (en) 2012-10-16
DE60142684D1 (de) 2010-09-09
AU2001259792B2 (en) 2005-12-22
AU5979201A (en) 2001-10-08
CA2404340A1 (en) 2001-10-04
EP1267909A4 (en) 2006-05-03
ATE475428T1 (de) 2010-08-15
WO2001072325A1 (en) 2001-10-04
EP1267909A1 (en) 2003-01-02
JP2004500110A (ja) 2004-01-08

Similar Documents

Publication Publication Date Title
DK1267909T3 (da) Fremgangsmåder til blokering af vævsdestruktion ved autoreaktive T-celler
Brentjens et al. Interstitial immune complex nephritis in patients with systemic lupus erythematosus
KR100426113B1 (ko) 티(t)-세포항원,및티(t)-세포매개증상의진단및치료에있어서의이의용도
Hart et al. Endogenously produced Ia antigens within cells of convoluted tubules of rat kidney.
EP0837696A4 (en) IMPROVED DELIVERY OF DIAGNOSTIC AND THERAPEUTIC SUBSTANCES AT ONE DESTINATION
DK1140170T3 (da) Antistoffragmenter til topisk behandling af öjensygdomme
ES2180754T3 (es) Compuestos y metodos para la deteccion de infeccion por t. cruzi.
EP0751992A4 (en) VASCULAR ENDOTHELIAL GROWTH FACTOR 2
KR927003816A (ko) Cd3에 대한 항체
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
FI973120A0 (fi) Ihmisen gp39:n eri epitoopeille spesifisiä monoklonaalisia vasta-aineita ja menetelmiä niiden käyttämiseksi diagnosoinnissa ja terapiassa
ATE506076T1 (de) Medizinische verwendung von anti-cs1 antikörpern
NO331072B1 (no) Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme.
TR200200781T1 (tr) Birlikte uyaran bir sinyal transdüksiyon molekülü olan ailime karşı insan monoklonal antikoru ve bunun farmasötik kullanımı
Hansen et al. A mouse aminopeptidase N is a marker for antigen‐presenting cells and appears to be co‐expressed with major histocompatibility complex class II molecules
KR960706560A (ko) 인화 항체 및 이것의 사용 방법(humanized antibodies and uses thereof)
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
SE0103754L (sv) Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
PT833911E (pt) Anticorpos anti-factor tecidular enxertados com cdr e metodos para a sua utilizacao
DE68925226D1 (de) Monoklonale Antikörper
MXPA03011499A (es) Proteinas de fusion de fce para el tratamiento de alergia y asma.
DE69638024D1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
DE69720241D1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
RU94045907A (ru) Вич-антитела человека или их фрагменты, экспрессионные кассеты, клетки-хозяева, фармацевтические композиции, способ защиты